The Leiden malaria group contributed to a study showing that hemozoin-mediated inflammasome activation limits long-lived anti-malarial immunity
In this study it is shown that deposition of the malarial pigment hemozoin directly limits the abundance and capacity of conventional type 1 dendritic cells to prime helper T cell responses. Hemozoin-induced dendritic cell dysfunction results in aberrant Plasmodium-specific CD4 T follicular helper cell differentiation, which constrains memory B cell and long-lived plasma cell formation. Mechanistically, we identify that dendritic cell-intrinsic NLRP3 inflammasome activation reduces conventional type 1 dendritic cell abundance, phagocytosis, and T cell priming functions in vivo. Published in Cell Reports
The Leiden malaria group contributed to a study showing that a pre-erythrocytic malaria, PfCSP mRNA vaccine candidate induces functional, protective immune responses against malaria in mice
Published in NPJ vaccines
Read more ...
The Leiden malaria group contributed to the development of a method for dissection-independent production of Plasmodium sporozoites from whole mosquitoes.
The development of a multi-step method is reported, based on batch processing of homogenised whole mosquitoes, slurry, and density-gradient filtration, which combined with free-flow electrophoresis rapidly produces a pure, infective sporozoite inoculum. Human-infective Plasmodium falciparum and rodent-infective Plasmodium berghei sporozoites produced in this way are two- to threefold more infective than salivary gland dissection sporozoites in in vitro hepatocyte infection assays. In an in vivo rodent malaria model, the same P. berghei sporozoites confer sterile protection from mosquito-bite challenge when immunisation is delivered intravenously or 60-70% protection when delivered intramuscularly. Published in Life Sci Alliance
Approval was gained for use of a second generation GAP, GA2, in humans by the Dutch Ministry of Infrastructure and the Environment (GGO IM-MV 20-018).
This second generation genetically attenuated parasite, GA2, has been developed in Leiden (LUMC) for development of a genetically attenuated malaria vaccine. GA2 parasites arrests growth late during development in liver, compared to GA1 parasites, which arrest early during liver stage development and which have been used in the first clinical trial of a genetically attenuated vaccine (Science Translational Medicine). The late growth arrest of GA2 broadens the array of antigens displayed to the immune system and extends the duration of parasite exposure to the immune system (compared to GA1, which arrest early during liver stage development).
The Leiden malaria group contributed to a study showing artemisinin exposure at the trophozoite stage impacts Plasmodium falciparum sexual conversion
Using a robust assay using gametocyte-reporter parasite lines to accurately measure the impact of drugs on sexual conversion rates, independently from their gametocytocidal activity, it was found that exposure to subcurative doses of the frontline antimalarial drug dihydroartemisinin (DHA) at the trophozoite stage resulted in a ~ fourfold increase in sexual conversion. Published in Elife
The Leiden malaria group contributed to a study showing that sporozoites induce regulatory macrophages
In this study human professional antigen-presenting cells responses to recombinant circumsporozoite protein, whiole sporozoites and and anti-CSP opsonized sporozoites both in monocyte derived macrophages and dendritic cells. The results of this study are a first step in enhancing our understanding of pre-erythrocytic natural immunity and the pitfalls of intradermal vaccination-induced immunity. Published in PloS Pathogens20/5
First clinical trial with genetically modified malaria vaccine completed
In an innovative study, LUMC and Radboudumc jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.
Read more ...
The Leiden malaria group contributed to preclinical evaluation of viral vector malaria vaccines expressing two liver stage antigens
Vaccination with a combination of the single-antigen vectors expressing PfLSA1 or PfLSAP2 was shown to improve protective efficacy compared to vaccination with each single-antigen vector alone. Vaccination with dual-antigen vectors expressing both PfLSA1 and PfLSAP2 resulted in responses to both antigens, particularly in outbred mice, and most importantly, the efficacy was equivalent to that of vaccination with a mixture of single-antigen vectors. Based on these promising data, dual-antigen vectors expressing PfLSA1 and PfLSAP2 will now proceed to manufacturing and clinical assessment under good manufacturing practice (GMP) guidelines. Published in Infection and Immunity
The Leiden malaria group contributed to a study of genome scale identification of essential metabolic processes of the Plasmodium liver stage
More than 1,300 barcoded P. berghei gene-deletion mutants were followed in a screen through the life cycle. We analyze the screen in the context of genomic, transcriptomic, and metabolomic data by building a thermodynamic model of P. berghei liver-stage metabolism. Seven metabolic subsystems were identified that become essential at the liver stages compared with asexual blood stages: type II fatty acid synthesis and elongation (FAE), tricarboxylic acid, amino sugar, heme, lipoate, and shikimate metabolism. Published in Cell
The Leiden malaria group contributed to a studyshowing that monocyte-derived CD11c+ cells acquire Plasmodium from hepatocytes to prime CD8 T cell immunity to liver-stage malaria
This study shows that a subset of liver-infiltrating monocyte-derived CD11c+ cells co-expressing F4/80, CD103, CD207, and CSF1R acquired parasites during the liver stage of malaria, but only after initial hepatocyte infection. These CD11c+ cells found in the infected liver and liver-draining lymph nodes exhibited transcriptionally and phenotypically enhanced antigen-presentation functions and primed protective CD8 T cell responses against Plasmodium liver-stage-restricted antigens. Published in Cell host Microbe
The Leiden malaria group contributed to Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate
Recently, a transgenic line of the rodent malaria parasite P. berghei (Pb) that expresses the P. falciparum (Pf) circumsporozoite protein (PfCS), and it was shown that this parasite line (PbVac) was capable of (1) infecting and developing in human hepatocytes but not in human erythrocytes, and (2) inducing neutralizing antibodies against the human Pf parasite. In this study PbVac was analyzed in detail and tools were developed necessary for its use in clinical studies. This pre-clinical safety assessment demonstrates that PbVac possesses all characteristics necessary to advance into clinical evaluation. Published in NPJ Vaccines
The Leiden malaria group contributed to a study developing a prime and target vaccination strategy that protects against liver-stage malaria in mice.
This alternative "prime and target" vaccination strategy aims specifically at inducing high numbers of tissue-resident memory T cells present in the liver at the time of hepatic infection. This approach bypasses the need for very high numbers of circulating T cells and markedly increases the efficacy of subunit immunization against liver-stage malaria with clinically relevant Ags and clinically tested viral vectors in murine challenge models. Translation to clinical use has begun, with encouraging results from a pilot safety and feasibility trial of intravenous chimpanzee adenovirus vaccination in humans. Published in SciTransl Med.
The Leiden malaria group contributed to a study aiming at development of a Plasmodium berghei sporozoite-based vaccination platform against human malaria.
A novel whole-sporozoite WSp malaria vaccine is described that employs transgenic sporozoites of rodent P. berghei (Pb) parasites as cross-species immunizing agents and as platforms for expression and delivery of PfCS (PbVac). PbVac is safe and induces functional immune responses in preclinical studies, warranting clinical testing and development. Published in NPJ Vaccines.
The Leiden malaria group contributed to a study showing that neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection.
Plasmodium species produce an ortholog of the cytokine macrophage migration inhibitory factor, PMIF, which modulates the host inflammatory response to malaria. Using a novel RNA replicon-based vaccine, the impact of PMIF immunoneutralization on the host response is shown and improved control of liver and blood-stage Plasmodium infection, and complete protection from re-infection is shown.Published in Nat Commun.
The Leiden malaria group contributed to a study demonstrating that a common PIEZO1 allele in African populations causes RBC dehydration and attenuates Plasmodium infection.
A novel human gain-of-function PIEZO1 allele, E756del, present in a third of the African population, was identified. RBCs from individuals carrying this allele are dehydrated and display reduced Plasmodium infection in vitro. This paper was published in Cell.
The Leiden malaria group contributed to a study demonstrating that host antibody responses to gametocyte proteins are associated with reduced malaria transmission efficiency from humans to mosquitoes.
Transmission inhibition is significantly associated with antibody responses to Pfs48/45, Pfs230, and to 43 novel gametocyte proteins assessed by protein microarray. This paper was published in Nature Communications
The Leiden malaria group contributed to a study showing that natural parasite exposure induces protective human anti-malarial antibodies.
In this study rare affinity-matured human NANP-reactive memory B cell antibodies elicited by natural Pf exposure were cloned and characterised that potently inhibited parasite transmission and development in vivo. This paper was published in Immunity
The LUMC Department of Parasitology have published a study that shows how protective immunity, after vaccination with attenuated malaria parasites, can vary depending on the route of administration and this is independent of the parasite load in the liver. This paper was published in Scientific Reports
In humans and murine models of malaria, intradermal immunization with genetically attenuated sporozoites that arrest in liver induces lower protective immunity than intravenous immunization. Our results indicate that the lower protection efficacy is obtained after intradermal sporozoite administration and that this is not linked to low hepatic parasite numbers as presumed before, but correlates with a shift towards regulatory immune responses. Overcoming these immune suppressive responses is important not only for live-attenuated malaria vaccines but also for other live vaccines administered in the skin.
The Leiden Malaria Group published a review on the use of transgenic parasites in malaria vaccine research. Published in Expert Rev Vaccines.
We review how transgenic malaria parasites are used, in vitro and in vivo, to determine protective efficacy of different antigens and vaccination strategies and to determine immunological correlates of protection. We describe how chimeric rodent parasites expressing P. falciparum or P. vivax antigens are being used to directly evaluate and rank order human malaria vaccines before their advancement to clinical testing. In addition, we describe how transgenic human and rodent parasites are used to develop and evaluate live (genetically) attenuated vaccines.
The Leiden Malaria Group contributed to studies showing that Plasmodium products persist in the bone marrow and promote chronic bone loss. Published in Science Immunology
It was found that malaria causes bone loss and growth retardation as a result of chronic bone inflammation induced by Plasmodium products. A malaria infection can severely suppress bone homeostasis, but the sustained accumulation of Plasmodium products in bone marrow induces MyD88-dependent inflammatory responses in osteoclast and osteoblast precursors, leading to increased RANKL expression and overstimulation of osteoclastogenesis that can result in bone resorption.
The Leiden Malaria Group contributed to studies identifying a protein (LIMP) that regulates sporozoite motility. Published in eLife
The Leiden Malaria Group contributed to studies characterising putative vaccine candidate antigens of Plasmodium vivax. Published in Scientific Reports and Clin Vaccine Immunol
In the first study the development of a highly protective CSP-based P. vivax vaccine is reported, a virus-like particle (VLP) known as Rv21, able to provide 100% sterile protection against a stringent sporozoite challenge in rodent models to malaria, where IgG2a antibodies were associated with protection in absence of detectable PvCSP-specific T cell responses. Protective efficacy against sporozoite challenge was assessed using novel chimeric rodent P. berghei parasites where the P. berghei csp gene has been replaced with either full-length P. vivax VK210 or the allelic VK247 csp.
In the second study 4 vaccine platforms, each targeting the human malaria parasite P. vivax cell-traversal protein for ookinetes and sporozoites (PvCelTOS), were generated and assessed for protective efficacy. These platforms consisted of a recombinant chimpanzee adenoviral vector 63 (ChAd63), a recombinant modified vaccinia virus Ankara (MVA), PvCelTOS conjugated to bacteriophage Qβ virus-like particles (VLPs), and a recombinant PvCelTOS protein expressed in eukaryotic HEK293T cells. Protective efficacy against sporozoite challenge was assessed using a novel chimeric rodent P. berghei parasite (Pb-PvCelTOS). This chimeric parasite expresses P. vivax CelTOS in place of the endogenous P. berghei CelTOS and produces fully infectious sporozoites. Despite the induction of anti-PvCelTOS antibodies and PvCelTOS-specific CD8+ T-cell responses, only low levels of protective efficacy against challenge with Pb-PvCelTOS sporozoites were obtained using any immunization strategy.
The Leiden Malaria Group contributed to a study showing the role of CD8+ T Cells during experimental cerebral malaria.
Published in PloS Pathogens
It is shown that CD8+ T Cells Induce Fatal Brainstem Pathology during Cerebral Malaria via Luminal Antigen-Specific Engagement of Brain Vasculature
The Leiden Malaria Group developed Modified CRISPR/Cas9 Constructs and Selection Protocol for the Rapid Generation of Marker-Free P. falciparum Fluorescent Reporter Lines
Published in Plos One
The CRISPR/Cas9 protocol we developed provides a simple set of tools to rapidly generate genetically modified P. falciparum lines, in particular transgenic parasites or gene-disruption and gene-mutation mutants that are free of any drug resistance genes. The absence of drug-resistance genes is particularly important in the creation of live genetically attenuated parasites that can be used as a malaria vaccine.
The Leiden Malaria Group published a study demonstrating that Variant Exported Blood-Stage Proteins Encoded by Plasmodium Multigene Families Are Expressed in Liver Stages Where They Are Exported into the Parasitophorous Vacuole
Published in PloS Pathogens
This is the first demonstration of expression of these proteins in the liver and evidence is presented that proteins of one family can transfer phosphatidylcholine in vitro. This is the first demonstration of a biological function of any exported variant protein family of rodent malaria parasites.
The Leiden Malaria Group contributed to a study identifying and characterizing a protein essential for the formation of the crystalloid and transmission of the malaria parasite. Published in Proc Natl Acad Sci U S A
We show that formation of the crystalloid - a unique and short-lived organelle of the Plasmodium ookinete and oocyst stage required for sporogony - is dependent on the precisely timed expression of an S-acyl-transferase, an enzyme involved in palmitoylation, a posttranslational modification of proteins (the addition of a C-16 long-chain fatty acid to a cysteine residue).
The Leiden Malaria Group contributed to a genome wide transcriptomic and proteomic analysis of separated male and female sexual cells of malaria parasites. Published in Nucleic Acids Research
This study revealed a large set highly expressed maternal transcripts without corresponding protein expression indicating large scale translational repression in P. falciparum female gametocytes for the first time.
The Leiden Malaria Group contributed to a study showing that the machinery underlying malaria parasite virulence is conserved between rodent and human malaria parasites. Published in Nature Communications
Sequestration of red blood cells infected with the human malaria parasite P. falciparum in organs such as the brain is considered important for pathogenicity. A similar phenomenon has been observed in mouse models of malaria, but it is unclear whether the P. falciparum proteins known to be involved in this process are conserved in the rodent parasite. In this study two proteins, SBP1 and MAHRP1, are identified that are conserved between rodent and human malaria parasites and that play a role in sequestration and virulence. These findings reveal evolutionary conservation of the machinery underlying sequestration of divergent malaria parasites and support the notion that the P. berghei rodent model is an adequate tool for research on malaria virulence.
The Leiden Malaria Group contributed to the development of a murine model for pre-clinical studies on pathology associated to malaria in pregnancy. Published in Infect. Immun.
Malaria infection during pregnancy leads to abortions, stillbirth, low birth weight and maternal mortality. Infected erythrocytes (IEs) accumulate in the placenta by adhering to chondroitin sulphate A (CSA) via var2CSA protein exposed on the IE membrane. P. berghei IE infection in pregnant BALB/c mice is a model for severe PM. We describe a transgenic P. berghei parasite expressing the full length var2CSA extracellular region (domains DBL1X-DBL6ϵ) fused to a P. berghei exported protein (EMAP1) and characterized a var2CSA-based mouse model of placental malaria (PM).
The Malaria Vaccines for the World (MVW)
The Malaria Vaccines for the World (MVW) meeting will take place this year in the LUMC (May 2-4th). This meeting, held once every 3 years, brings together the world’s leading academic and industrial scientists, as well as international regulators, funders and government agencies.
The meeting will describe different aspects of vaccine development, assessment and deployment, as well as funding and regulatory aspects of vaccine implementation and testing. See here for more details.
The Leiden Malaria Group contributed to a study that showed that the multidrug resistance-associated protein 2 (MDR2) is essential for malaria parasite development in the liver (published in Cell Microbiol)
Both P. falciparum MRP2-deficient parasites and P. berghei mutants lacking MRP protein expression abort in mid- to late liver stage development, failing to produce mature liver stages. The combined P. berghei and P. falciparum data are the first demonstration of a critical role of an ABC transporter during malaria parasite liver stage development.
The Leiden Malaria Group contributed to a study that analysed motility of malaria parasites in the skin (published in Elife)
Sporozoite motility and their interaction with dermal blood vessels was analysed using intravital microscopy in mice. Evidence is provided that sporozoites exhibit different types of motility, which is important for successful exit from the inoculation site and invasion of blood vessels.
The Leiden Malaria Group contributed to a study that analysed cytosolic immune responses of host hepatocytes against malaria infection (published in Autophagy)
Both autophagy and nonselective cannonical autophagy events were analysed.
The Leiden Malaria Group contributed to a study that identified two protective liver-stage candidates (published in Sci Rep.)
Chimeric P. berghei parasites expressing the cognate P. falciparum antigen were used to test protective efficacy in mice that were immunised with 10 different P. falciparum vaccine candidate antigens
A Leiden study published in Journal of Experimental Medicine showed that, unexpectedly, malaria parasites can develop without digesting haemoglobin but are restricted to young red blood cells (reticulocytes) for their development and become insensitive to the action of chloroquine.
The Leiden Malaria Group contributed to a study that identified a phospholipase that is involved in disruption of the liver stage parasitophorous vacuole membrane (published in Plos Pathogens)
Dr. Meta Roestenberg, dr. Shahid Khan and prof. Ko Willems van Dijk (Departments of Parasitology and Human Genetics), received a Van de Kamp Fonds-grant (€ 250.000) for research on malaria parasite development in the liver
Dr. Meta Roestenberg received the Gisela Thier Fellowship for research on malaria; specifically to investigate the development of parasites in the liver.
The Leiden Malaria group in collaboration with RadboudUMC published a paper about a genetically modified parasite vaccine (GAP) against malaria, which is now ready for testing in humans (published ineLIFE).
This is an important milestone for malaria research in Leiden and is the culmination of studies that were first initiated here in the mid-90s:
- The Leiden Malaria group was the first group to develop genetic modification in malaria parasites (2 papers published in Science in 1996 and 1997)
- Through analysis of gene-deletion mutants in rodent models of malaria, we discovered that it was possible to create attenuated parasites, which were able to invade the liver but were unable to proceed into the pathogenic blood stage infection. Importantly mice infected (immunised) with these live-attenuated parasites developed protective immunity against an infection with wild type parasites (published in PNAS in 2005).
- In 2008, in the group of Shahid Khan, we started to work on translating these findings into a human vaccine against malaria. This was performed in collaboration with the RadboudUMC (Nijmegen) and the US company Sanaria, and was supported by a grant provided by TI-Pharma. This involved testing and refining many live genetically-attenuated vaccines until we could demonstrate that one met all the necessary pre-clinical safety and protective efficacy standards; it is now ready to advance into testing in humans.
More details on the generation and pre-clinical characterisation of this vaccine can be found in 2 papers published in 2014; one published in the FASEB Journal in May and one that has just appeared in eLIFE.
The Leiden Malaria Group contributed to a study that identified the maternal mRNA contribution to post-fertilization development of P. berghei using RNA immunoprecipitation and microarray analysis (published in Genome Biology).
Following fertilization, the early proteomes of metazoans are defined by the translation of stored but repressed transcripts; further embryonic development relies on de novo transcription of the zygotic genome. Evidence is presented that mRNA of >700 genes is translationally repressed in the female gametocyte which is the precursor cell of the female gamete. These mRNAs are associtated with DOZI and CITH which are translational repressor proteins.
The Leiden Malaria Group recently contributed to a paper entitled ‘A comprehensive evaluation of rodent malaria parasite genomes and gene expression’ (published in BMC Biology)
The consortium that contributed to this study consisted of teams from the Wellcome Trust Sanger Institute (UK), RUMC and LUMC (The Netherlands), NIMR, Univ. of Glasgow and Univ. of Oxford (UK). These analyses resulted in full-length gene models for more than 98% of predicted RMP protein-coding genes. Approximately 60% of these genes have functional annotation, which is comparable to the percentage of functionally annotated genes in the P. falciparum 3D7 reference genome. A high percentage (~90%) of the predicted RMP proteins have orthologs in primate malaria species. This high level of orthology and gene conservation between RMP and primate malaria genomes further supports the use of RMP as experimental models to characterize Plasmodium gene function.
Dr Shahid Khan and Dr Chris Janse of the Leiden Malaria Research Group received a pilot grant of $70,000 from the PATH Malaria Vaccine Initiative (MVI) , an organization established and largely supported by the Bill & Melinda Gates Foundation. This pilot grant has been awarded to examine a novel live genetically-modified malaria-parasite vaccine, which is designed to provide immunity against multiple stages of the malaria parasite. This so called stage-transcending vaccine has been engineered to express malaria-vaccine candidate antigens from different points of the parasite life-cycle in sporozoites, the infectious forms of the parasite that are injected by the mosquito. The Leiden Malaria Research Group are pioneers and leaders in the field of genetic modification of malaria parasites and vaccine research. The pilot study will be first performed in rodents and, if successful, the intention in a second phase to develop this platform for human vaccination.
The Leiden Malaria Group have published a study on Plasmodium mutants expressing Ovalbumin (OVA)(published in Infect. Immunity). They show that the subcellular location of Ovalbumin in Plasmodium berghei blood stages influences the magnitude of T-cell responses.
Dr Shahid Khan and Dr Chris Janse of the Leiden Malaria Research Group received a grant of $340,000 from the PATH Malaria Vaccine Initiative (MVI), an organization established and largely supported by the Bill & Melinda Gates Foundation. The grant has been awarded to develop a number of genetically modified rodent malaria parasites that express proteins from the most virulent human malaria parasite, Plasmodium falciparum. As evaluating malaria vaccine efficacy in humans is difficult, very expensive and highly time consuming these ‘humanized parasites’ will be used in rodents, to rapidly evaluate which vaccines against human malaria-parasite proteins are likely to be most effective in controlling a malaria infection. This research that is being carried out in collaboration with researchers from Seattle BioMed and Johns Hopkins University (both USA) and the best candidates will be directly translated into clinical trials and help inform the final composition of an effective malaria vaccine
The Leiden Malaria Group have published a study identifying and characterizing new members of the malaria parasite's 6-Cys family of proteins (published in FASEB J).
These proteins have critical roles throughout parasite development and are being pursued as targets in anti-malaria vaccination strategies. We show that a number of 6-Cys proteins have critical but distinct roles in the establishment and maintenance of a parasitophorous vacuole and subsequent liver-stage development. Specifically, we identify one member (B9) as a potential target to create genetically attenuated parasites suitable for vaccination.
PhD thesis: Jingwen Lin (LUMC, Leiden). Generation of genetically attenuated blood-stage malaria parasites; characterizing growth and virulence in a rodent model of malaria.Read more ....
The Leiden Malaria Research group contributed to a study analysing malaria rhomboid proteases (published in Molecular Microbiology)
Rhomboid-like proteases cleave membrane-anchored proteins within their transmembrane domains. In apicomplexan parasites substrates include molecules that function in parasite motility and host cell invasion. While twoPlasmodium rhomboids, Rhomboid 1 and rhomboid 4, have been examined, the roles of the remaining six rhomboids during the malaria parasite's life cycle are unknown. We present systematic gene deletion analyses of all eight Plasmodium rhomboid-like proteins as a means to discover stage-specific phenotypes and potential functions in the rodent malaria model, P. berghei.
The Leiden Malaria Research group contributed to a study analysing anti-merozoite malaria vaccine candidates using the rodent model Plasmodium berghei (published in Science Reports)
An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum.
The Leiden Malaria Research group contributed to a study showing that Hemozoin induces lung inflammation and correlates with Malaria-Associated Acute Respiratory Distress Syndrome (published in Am J Respir Cell Mol Biol.)
Malaria-associated acute respiratory distress syndrome (MA-ARDS) is a deadly complication and its pathophysiology is insufficiently understood. Both in humans and mouse models, MA-ARDS is characterized by marked pulmonary inflammation. By quantifying hemozoin in the lungs and measuring disease parameters of MA-ARDS, we demonstrate a highly significant correlation between pulmonary hemozoin levels, lung weight, alveolar edema and pulmonary inflammation.
The Leiden Malaria Research group contributed to the generation of fluorescent P. cynomolgi liver stages enabling live imaging and purification of hypnozoite-forms (published in PloS One).
A major challenge for strategies to combat the human malaria parasite P. vivax is the presence of hypnozoites in the liver. These dormant forms can cause renewed clinical disease after reactivation through unknown mechanisms. The closely related non-human primate malaria P. cynomolgi is a frequently used model for studying hypnozoite-induced relapses. The generation of the first transgenic P. cynomolgi parasites that stably express fluorescent markers in liver stages enabled live imaging and purification of hypnozoite-forms (hypnozoites)
The Leiden Malaria Research group contributed to a study showing the rodent parasite Plasmodium berghei blood stages export a large and diverse repertoire of proteins into the red blood cell (published in Mol Cell Proteomics).
This study indicates that P. berghei traffics a diverse range of proteins to different cellular locations into the host red blood cell by mechanisms that are analogous to those employed by the human parasite P. falciparum. This information can be exploited to generate transgenic humanized rodent P. berghei parasites expressing chimeric P. berghei/P. falciparum proteins on the surface of rodent irbc, thereby opening new avenues for in vivo screening adjunct therapies that block sequestration.
The Leiden Malaria Research group contributed to a study showing that male gametes of malaria parasites evolve faster than female gametes (published in Evolution, Medicine and Public Health). Read more ..
The Leiden Malaria group published four methods papers in the book: Malaria: Methods and protocols (Methods in Molecular Biology) edited by Robert Menard
- Screening inhibitors of P. berghei blood stages using bioluminescent reporter parasites. Link....
- Quantitative analysis of Plasmodium berghei liver stages by bioluminescence imaging. Link....
- Bioluminescence imaging of P. berghei Schizont sequestration in rodents. Link....
- Bioluminescence imaging of P. berghei Schizont sequestration in rodents. Link....
The Leiden Malaria Research group contributed to a study showing that malaria parasites interfere with the development of immunological memory through expression of an ortholog of macrophage migration inhibitory factor, MIF (published in PNAS)
Malaria parasites interfere with the development of immunological memory through expression of an ortholog of macrophage migration inhibitory factor (MIF). This cytokine enhanced inflammatory cytokine production and also induced antigen-experienced CD4 T cells to develop into short-lived effector cells rather than memory precursor cells.
The Leiden Malaria Research Group and collaborators wrote a review on genetic engineering of attenuated malaria parasites for vaccination (published in Curr. Opin. Biotechnol.).
Vaccination with live-attenuated Plasmodium sporozoites that arrest in the liver can completely protect against a malaria infection both in animal models and in humans. Advances in genetic manipulation of Plasmodium has enabled new approaches to design genetically attenuated parasites (GAPs). Tthe principles in discovery and development of GAPs in preclinical models that are important in selecting GAP parasites for first-in-human clinical studies are dicsussed in this review. The challenges in manufacture, formulation and delivery of a live-attenuated whole parasite malaria vaccine are highlighted, as well as the further refinements that may be implemented in the next generation GAP vaccines.
The Leiden Malaria Research Group and collaborators report on an approach for assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates (published in Vaccine)
The critical first step in the clinical development of a malaria vaccine, based on live-attenuated Plasmodium falciparum sporozoites, is the guarantee of complete arrest in the liver. We report an approach for assessing adequacy of attenuation of genetically attenuated sporozoites in vivo using the Plasmodium berghei model of malaria and P. falciparum sporozoites cultured in primary human hepatocytes.
The Leiden Malaria Research Group contributed to a paper discussing the role of animal models for research into development of new treatments for severe malaria (published in Plos Pathogens)
In light of the recent controversies over the role of animal models for research into the development of new treatments for severe malaria, particularly cerebral disease, a group of scientists came together to discuss the relative merits of a range of animal models and their overlap with the complex clinical syndromes of human disease.
The Leiden Malaria Research Group developed and published a novel method (GIMO transfection) for transgene expression and gene complementation in rodent malaria parasites (published in PlosOne ).
Compared to existing protocols the novel methods of GIMO-transfection greatly simplifies and speeds up the generation of mutants expressing heterologous proteins, free of drug-resistance genes, and requires far fewer laboratory animals. In addition we demonstrate that GIMO-transfection is also a simple and fast method for genetic complementation of mutants with a gene deletion or mutation.
The Leiden Malaria Research Group and collaborators showed that CD36-mediated tissue sequestration of malaria parasites is beneficial for growth of the parasites (published in J. Exp. Med) .
These results reveal for the first time the importance of sequestration to a malaria infection, with implications for the development of strategies aimed at reducing pathology by inhibiting tissue sequestration.